Artificial intelligence is rapidly becoming embedded across the pharmaceutical industry, from drug discovery to commercialization. Yet as adoption accelerates, many organizations remain unclear about where AI creates real value and where it simply adds complexity.

Rather than treating AI as a set of isolated use cases, pharma leaders should approach it as a decision-support capability, applying it selectively to strengthen judgment and execution across the drug lifecycle.